Zai Lab Doses First Patient in Phase III Trial of ZL-2306 (niraparib) in Patients with Small-Cell Lung Cancer in China

World News: . []

SHANGHAI China Aug 28 2018 GLOBE NEWSWIRE -- Zai Lab LINK  NASDAQ ZLAB a Shanghai-based innovative biopharmaceutical company today LINK  dosing of the first patient in a Phase III trial of LINK  niraparib in patients with smal l-cell ...

More news and information about Zai Lab Limited

Published By:

Globe Newswire: 12:30 GMT Tuesday 28th August 2018

Published: .

Search for other references to "doses" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us